NASDAQ: IRTCIrhythm Technologies Inc Stock
$111.27-5.16 (-4.43%)
Updated Apr 25, 2024
IRTC Price
$111.27
Fair Value Price
-$74.97
Market Cap
$3.45B
52 Week Low
$70.24
52 Week High
$135.80
P/E
-27.54x
P/B
16.41x
P/S
6.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$492.68M
Earnings
-$123.41M
Gross Margin
67.3%
Operating Margin
-24.15%
Profit Margin
-25%
Debt to Equity
1.06
Operating Cash Flow
-$50M
Beta
1.21
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
IRTC Overview
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IRTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRTC ($111.27) is overvalued by 248.42% relative to our estimate of its Fair Value price of -$74.97 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IRTC ($111.27) is not significantly undervalued (248.42%) relative to our estimate of its Fair Value price of -$74.97 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IRTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IRTC due diligence checks available for Premium users.
Be the first to know about important IRTC news, forecast changes, insider trades & much more!
IRTC News
Valuation
IRTC fair value
Fair Value of IRTC stock based on Discounted Cash Flow (DCF)
Price
$111.27
Fair Value
-$74.97
Undervalued by
248.42%
IRTC ($111.27) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRTC ($111.27) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-27.54x
Industry
29.73x
Market
40.97x
IRTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
16.41x
Industry
3.71x
IRTC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IRTC's financial health
Profit margin
Revenue
$132.5M
Net Income
-$38.7M
Profit Margin
-29.2%
IRTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IRTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$433.1M
Liabilities
$223.0M
Debt to equity
1.06
IRTC's short-term assets ($230.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRTC's short-term assets ($230.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRTC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$16.0M
Investing
$1.4M
Financing
$3.5M
IRTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IRTC vs Medical Device Stocks
Irhythm Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.